Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma | Zendy

Stacy Loeb | Zendy; Yasin Folkvaljon | Zendy; Mats Lambe | Zendy; David Robinson | Zendy; Hans Garmo | Zendy; Christian Ingvar | Zendy; Pär Stattin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma

Author(s) -

Stacy Loeb,

Yasin Folkvaljon,

Mats Lambe,

David Robinson,

Hans Garmo,

Christian Ingvar,

Pär Stattin

Publication year - 2015

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2015.6604

Subject(s) - medicine , vardenafil , medical prescription , melanoma , tadalafil , erectile dysfunction , sildenafil , cgmp specific phosphodiesterase type 5 , population , relative risk , cancer , oncology , pharmacology , confidence interval , cancer research , environmental health

The target for the oral erectile dysfunction drugs, phosphodiesterase type 5 (PDE5) inhibitors, is part of a pathway implicated in the development of malignant melanoma. An increased risk of melanoma in sildenafil users was recently reported.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research